Side Effects of entrectinib: A Synthesis of Findings from 12 Studies

  1. Home
  2. Side Effects of entrectinib
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Side Effects of entrectinib: A Synthesis of Findings from 12 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Side Effects of entrectinib: A Synthesis of Findings from 12 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Main Research Findings

Multiple studies have shown that entrectinib is an effective treatment for various types of tumors with NTRK gene fusion mutations. 11 、 10 、 4 、 6 Entrectinib showed dramatic effects in patients with malignant peripheral nerve sheath tumor (MPNST) with NTRK gene fusion mutations. 11 Entrectinib has also been shown to be effective in patients with brain metastases. 4 Entrectinib is generally considered a safe drug, but some patients may experience side effects. 9

Reason for Side Effects

Entrectinib side effects are thought to be related to the inhibition of the NTRK pathway. 2 The NTRK pathway plays an important role in the development and maintenance of the nervous system, and inhibiting this pathway can affect nervous system function. 2

Common Side Effects

Dizziness

Dizziness has been reported as a side effect of entrectinib. 1 、 2 This side effect is thought to be caused by the inhibition of the NTRK pathway, which affects areas of the brain involved in balance. 2

Weight Gain

Weight gain has been reported as a side effect of entrectinib. 1 、 2 This side effect is thought to be caused by the inhibition of the NTRK pathway, which affects metabolism. 2

Weakness

Weakness has been reported as a side effect of entrectinib. 2 This side effect is thought to be caused by the inhibition of the NTRK pathway, which affects nervous system function. 2

Numbness

Numbness has been reported as a side effect of entrectinib. 2 This side effect is thought to be caused by the inhibition of the NTRK pathway, which affects nervous system function. 2

Countermeasures for Side Effects

Countermeasures for Dizziness

If you experience severe dizziness, you should consult your doctor and consider treatments such as medication. 1

Countermeasures for Weight Gain

Diet and exercise are effective measures to prevent weight gain. 1

Countermeasures for Weakness

If you are concerned about weakness, you should consult your doctor and consider treatments such as medication. 2

Countermeasures for Numbness

If you are concerned about numbness, you should consult your doctor and consider treatments such as medication. 2

Comparison of Studies

Common Points of Studies

Multiple studies have shown that entrectinib is an effective treatment for tumors with NTRK gene fusion mutations. 11 、 10 、 4 、 6 Entrectinib is generally considered a safe drug, but some patients may experience side effects. 9

Differences in Studies

Each study has different target tumor types and treatment courses. 11 、 10 、 4 、 6 Therefore, the results obtained from each study cannot be directly applied to other cases. 11 、 10 、 4 、 6

Precautions for Real-Life Applications

Entrectinib is an effective treatment for tumors with NTRK gene fusion mutations, but the possibility of side effects should be considered. 11 、 10 、 4 、 6 If you are considering taking entrectinib, consult your doctor and determine the right treatment for your situation. 11 、 10 、 4 、 6

Limitations of Current Research

Research on entrectinib is still in its early stages, and further investigation is needed to understand its long-term effects and safety. 11 、 10 、 4 、 6 Resistance to entrectinib is also a future challenge. 7

Future Research Directions

Further research is needed to clarify the long-term effects and safety of entrectinib, as well as the mechanisms of resistance. 11 、 10 、 4 、 6 Research on combination therapy with entrectinib and other treatments should also be pursued. 11 、 10 、 4 、 6

Conclusion

Multiple studies have shown that entrectinib is an effective treatment for tumors with NTRK gene fusion mutations. 11 、 10 、 4 、 6 However, there is also the possibility of side effects, so if you are considering taking entrectinib, consult your doctor and determine the right treatment for your situation. 11 、 10 、 4 、 6 Research on entrectinib is still in its early stages, and further investigation is needed. 11 、 10 、 4 、 6

Literature analysis of 12 papers
Positive Content
12
Neutral Content
0
Negative Content
0
Article Type
0
0
0
8
10
1.

TRK inhibitor activity and resistance in TRK fusion-positive cancers in adults.

Author: HaradaGuilherme, DrilonAlexander

TRK fusion cancer treatment
TRK inhibitor side effects

TRK inhibitors, such as larotrectinib and entrectinib, demonstrate high response rates and durable disease control in TRK fusion-positive cancers, including intracranial activity. On-target side effects include dizziness, weight gain, and withdrawal pain. Resistance mechanisms have led to the development of next-generation TRK inhibitors.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.

Language : English

2.

TRK inhibitors in TRK fusion-positive cancers.

Author: DrilonA

Brain metastasis treatment
TRK fusion-positive cancer
Dizziness
Weight gain

TRK fusions are oncogenic drivers of various cancers. First-generation TRK inhibitors, larotrectinib and entrectinib, have shown efficacy in treating TRK fusion-positive cancers, including those with brain metastases. Next-generation TRK inhibitors, such as selitrectinib and repotrectinib, are being developed to address on-target resistance. TRK inhibitors have a favorable safety profile, but certain on-target adverse events should be monitored in the clinic.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

3.

TRK inhibitors in TRK fusion-positive cancers.

Author: DrilonA

Durable responses
Intracranial activity
Dizziness
Paraesthesias
Weight gain

TRK inhibitors, such as larotrectinib and entrectinib, are effective in treating various cancers with TRK fusions, including those with brain metastases. While resistance can occur, next-generation inhibitors like selitrectinib and repotrectinib are being developed to overcome this. Although TRK inhibitors have a good safety profile, some on-target side effects like weight gain and dizziness can occur.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

4.

Evolving role of entrectinib in treatment of <i>NTRK</i>-positive tumors.

Author: ChawlaNeal, BuiNam Q, SeetharamMahesh

Tumor treatment

This abstract describes the efficacy and safety of entrectinib, a first-generation Trk inhibitor, in the treatment of <i>NTRK</i> fusion positive solid tumors and <i>ROS1</i> positive non-small-cell lung cancers. The study highlights the impressive activity of entrectinib, particularly in patients with intracranial metastasis.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

6.

Case Report: A case of complete response to entrectinib in <i>NTRK</i> fusion gene-positive parotid gland cancer.

Author: MoriyamaEtsuko, NagasuSachiko, TanakaToshimitsu, ShimotsuuraYasutaka, OnoTakeharu, UmenoHirohito, AkibaJun, KawaharaAkihiko, FujitaFumihiko, KawaguchiTakumi, MiwaKeisuke

Cancer treatment
Disease progression

Comprehensive genomic profiling revealed a previously unreported gene fusion involving the MLLT4 and ZNF444 genes in a patient with mammary analog secretory carcinoma (MASCA) who experienced local recurrence and cervical lymph node metastases. This information may have implications for targeted therapies for MASCA.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.

Language : English

7.

Recent advances in the discovery of tropomyosin receptor kinases TRKs inhibitors: A mini review.

Author: El-NassanHala B, Al-QadhiMustafa A

TRK-fusion positive solid tumor treatment
CNS side effects
Drug resistance

This review highlights the efforts done during the last three years in the design and discovery of novel TRK inhibitors, emphasizing the challenges of overcoming acquired drug resistance and minimizing CNS side effects.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

8.

Identification of dual STRN-NTRK2 rearrangements in a high grade sarcoma, with good clinical response to first-line larotrectinib therapy.

Author: LinRuihe, MallickAtrayee Basu, WangZi-Xuan, BrownScot Andrew, LuBo, JiangWei

Tumorigenesis inhibition

NTRK2 gene fusions are involved in tumorigenesis of various tumors, and selective Trk tyrosine kinases inhibitors like larotrectinib and entrectinib have shown significant efficacy in treating these tumors.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

9.

Safety of current treatment options for NTRK fusion-positive cancers.

Author: YangAdeline T, LaetschTheodore Willis

Cancer treatment
Resistance mechanisms
Side effects

Oncogenic NTRK fusions are found in multiple cancer types and can be treated with tropomyosin receptor kinase inhibitors (TRKi). Larotrectinib and entrectinib are two TRKi that are FDA approved for tissue agnostic cancer treatment. As experience with TRKi grows, new mechanisms of resistance and side effects are being identified.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

10.

TRUST-II: a global phase II study of taletrectinib in <i>ROS1</i>-positive non-small-cell lung cancer and other solid tumors.

Author: NagasakaMisako, OheYuichiro, ZhouCaicun, ChoiChang-Min, YangNong, LiuGeoffrey, FelipEnriqueta, PérolMaurice, BesseBenjamin, NievaJorge, RaezLuis, PennellNathan A, DimouAnastasios, MarinisFilippo de, CiardielloFortunato, SetoTakashi, HuZheyi, PanMax, WangWeiqing, LiShuanglian, OuSai-Hong I

Brain metastasis treatment
ROS1+ NSCLC treatment
Neurological side effects

Taletrectinib is a new ROS1 inhibitor designed to improve efficacy, overcome resistance to first-generation ROS1 inhibitors, and address brain metastasis while minimizing neurological side effects. This abstract describes the rationale and design of TRUST-II, a global phase II study of taletrectinib in patients with ROS1 fusion-positive (ROS1+) non-small-cell lung cancer and other ROS1+ solid tumors.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

11.

Dramatic response to entrectinib in a patient with malignant peripheral nerve sheath tumor harboring novel SNRNP70-NTRK3 fusion gene.

Author: KobayashiHiroshi, MakiseNaohiro, Shinozaki-UshikuAya, ZhangLiuzhe, IshibashiYuki, IkegamiMasachika, TsudaYusuke, KohsakaShinji, UshikuTetsuo, OdaKatsutoshi, MiyagawaKiyoshi, AburataniHiroyuki, ManoHiroyuki, TanakaSakae

MPNST treatment
Tumor response
Side effects

This study describes a case of a patient with malignant peripheral nerve sheath tumor (MPNST) with a rare gene rearrangement involving the neurotropic tropomyosin receptor kinase (NTRK) gene. MPNST is a rare and aggressive cancer. The researchers found that the patient responded well to treatment with entrectinib, an NTRK inhibitor. This case highlights the importance of genetic testing for MPNST, especially using RNA panels to detect rare fusion genes.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.